SPRC - EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA Ibogaine And Ketamine Compounds | Benzinga
On Tuesday, Clearmind Medicine Inc (NASDAQ:CMND) submitted three additional patent applications under the international Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd (NASDAQ:SPRC).
The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), Ibogaine, and Ketamine, each with Palmitoylethanolamide (PEA), the active ingredient of SciSparc’s proprietary CannAmide.
These were previously filed as provisional patent applications with the United States Patent and Trademark Office (USPTO).
Overall, as part of this collaboration, eight other patent applications have been filed by Clearmind with the USPTO for various combinations, 3 of them for the combination ...